Evidence map›Paper›PMID 36114357›Full record

ArticleCommunications biology2022

Mechanism of action of non-camptothecin inhibitor Genz-644282 in topoisomerase I inhibition.

Masahiro Nishida, Takeshi Terabayashi, Shigeru Matsuoka, Tomoko Okuma, Sawako Adachi, Tadashi Tomo, Masanori Kawano, Kazuhiro Tanaka, Hiroshi Tsumura, Hirofumi Anai and 3 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Masahiro Nishida *Clinical Engineering Research Centre, Oita University, Yufu, Oita, Japan.
Takeshi Terabayashi *Department of Pharmacology, Oita University, Yufu, Oita, Japan.ORCID 0000-0001-7102-784X
Shigeru MatsuokaDepartment of Clinical Pharmacology & Therapeutics, Oita University, Yufu, Oita, Japan.
Tomoko OkumaDepartment of Obstetrics and Gynecology, Oita University, Yufu, Oita, Japan.
Sawako AdachiDepartment of Obstetrics and Gynecology, Oita University, Yufu, Oita, Japan.
Tadashi TomoClinical Engineering Research Centre, Oita University, Yufu, Oita, Japan.
Masanori KawanoDepartment of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Kazuhiro TanakaDepartment of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Hiroshi TsumuraDepartment of Orthopaedic Surgery, Faculty of Medicine, Oita University, Yufu, Oita, Japan.
Hirofumi AnaiClinical Engineering Research Centre, Oita University, Yufu, Oita, Japan.
Toshimasa IshizakiDepartment of Pharmacology, Oita University, Yufu, Oita, Japan.
Yoshihiro NishidaDepartment of Obstetrics and Gynecology, Oita University, Yufu, Oita, Japan. ynishida@oita-u.ac.jp.
Katsuhiro HanadaClinical Engineering Research Centre, Oita University, Yufu, Oita, Japan. hanada@oita-u.ac.jp.ORCID 0000-0003-0429-1899
Oita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Topoisomerase I (TOP1) controls the topological state of DNA during DNA replication, and its dysfunction due to treatment with an inhibitor, such as camptothecin (CPT), causes replication arrest and cell death. Although CPT has excellent cytotoxicity, it has the disadvantage of instability under physiological conditions. Therefore, new types of TOP1 inhibitor have attracted particular attention. Here, we characterised the effect of a non-camptothecin inhibitor, Genz-644282 (Genz). First, we found that treatment with Genz showed cytotoxicity by introducing double-strand breaks (DSBs), which was suppressed by co-treatment with aphidicolin. Genz-induced DSB formation required the functions of TOP1. Next, we explored the advantages of Genz over CPT and found it was effective against CPT-resistant TOP1 carrying either N722S or N722A mutation. The effect of Genz was also confirmed at the cellular level using a CPT-resistant cell line carrying N722S mutation in the TOP1 gene. Moreover, we found arginine residue 364 plays a crucial role for the binding of Genz. Because tyrosine residue 723 is the active centre for DNA cleavage and re-ligation by TOP1, asparagine residue 722 plays crucial roles in the accessibility of the drug. Here, we discuss the mechanism of action of Genz on TOP1 inhibition.

Indexed as

CamptothecinDNA Topoisomerases, Type IAphidicolinArginineAsparagineDNANaphthyridinesTyrosineAphidicolinArginineAsparagineCamptothecinDNADNA Topoisomerases, Type IGenz-644282NaphthyridinesTyrosine

Identifiers

PMID36114357
PMCPMC9481636
OpenAlexW4296162119

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.